SFI
PSTV icon

Susquehanna Fundamental Investments’s Plus Therapeutics PSTV Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-35
Closed -$33K – 1858
2021
Q2 		$33K Buy
+35
New +$31.6K ﹤0.01% 1634

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Susquehanna Fundamental Investments's PSTV Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Plus Therapeutics (PSTV) in Q3 2021, closing a stake of 35 shares — an estimated $33K sold.

Susquehanna Fundamental Investments first reported a position in PSTV in Q2 2021 and held it in 1 quarter. The position peaked at $33K in Q2 2021. 11 funds tracked by Wall St. Rank hold PSTV as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining Plus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 35 Plus Therapeutics shares in Q3 2021, an estimated $33K.
  • Susquehanna Fundamental Investments first reported a position in Plus Therapeutics in Q2 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Plus Therapeutics position peaked at $33K in Q2 2021.
  • 11 funds tracked by Wall St. Rank held Plus Therapeutics as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.